EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies

Muhammad Hammad, Sadaf Fardoos, Khadija Shakoor

Exploration of Neuroprotective Therapy · 07.07.2026 · 6

DOI: 10.37349/ent.2026.1004162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Neuroprotective Therapy, online erschienen am 07.07.2026. Verfasst von Muhammad Hammad und 2 weiteren Autor:innen. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative and neurodevelopmental neurological disorders represent a growing global health burden, characterized by progressive neuronal dysfunction, cognitive decline, and impaired functional outcomes. Increasing evidence highlights neuroinflammation as a central pathophysiological mechanism linking mitochondrial dysfunction, oxidative stress, microbiota dysbiosis, and synaptic impairment across diverse neurological conditions. This narrative review was conducted using a structured literature search approach, incorporating major biomedical databases to enhance transparency and reproducibility. This review synthesizes contemporary evidence on mechanistic pathways underlying neuroinflammation-mediated neurodegeneration and critically evaluates emerging neuroprotective therapeutic strategies. Particular emphasis is placed on mitochondrial transfer approaches, novel circulating and imaging biomarkers, and integrative neurotechnological innovations such as artificial intelligence-driven neuroimaging analytics. While several therapeutic approaches demonstrate promise in preclinical models, most remain at early experimental or translational stages, with limited validation in large-scale human studies. Current findings suggest that targeting neuroimmune signaling cascades, restoring mitochondrial bioenergetics, and modulating gut-brain axis interactions may provide synergistic neuroprotective benefits. The review proposes a multidimensional precision-medicine framework incorporating biomarker-guided therapeutic selection and interdisciplinary care models. Future research priorities include longitudinal biomarker validation, randomized clinical trials of mitochondrial-based therapies, and integration of digital neurodiagnostic platforms to enhance early disease detection. Despite these advances, significant gaps remain in clinical translation, standardization of biomarkers, and long-term therapeutic safety, necessitating cautious interpretation of emerging evidence.

Zitieren

APA

Hammad, M., Fardoos, S., & Shakoor, K. (2026). Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies. Exploration of Neuroprotective Therapy, 6. https://doi.org/10.37349/ent.2026.1004162

Vancouver

Hammad M, Fardoos S, Shakoor K. Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies. Exploration of Neuroprotective Therapy. 2026;6. doi:10.37349/ent.2026.1004162

BibTeX
@article{Hammad2026,
  author = {Hammad, Muhammad and Fardoos, Sadaf and Shakoor, Khadija},
  title = {Neuroinflammation-driven neurodegeneration: emerging biomarkers, mitochondrial therapeutics, and translational neuroprotective strategies},
  journal = {Exploration of Neuroprotective Therapy},
  year = {2026},
  volume = {6},
  doi = {10.37349/ent.2026.1004162}
}
Kostenlos starten →